

REMARKS

The application has been amended to insert the required reference to the parent applications, for which benefit is claimed, of this new continuing application.

Claims 1-8 and 14-22 are pending, with claims 1, 14, 15, and 16 being independent. Claims 1, 2, 8, and 14-17 have been amended, and claims 9-13 have been canceled, all without prejudice to pursuing canceled subject matter in a continuing application, and without disclaiming any subject matter.

Claims 1, 2, 8, and 14-16 have been amended to claim those compounds in which A¹ is a heteroaryl residue. Support for this amendment can be found throughout the application as originally filed, and in the specification on page 8, line 11. The proviso appearing at the end of claim 1 has been deleted because it is no longer needed: it excluded compounds in which A¹ was other than a heteroaryl residue. Those claims have also been amended to claim those compounds in which A² is a benzene ring, a naphthalene ring, or a carbocycle. Support for this amendment also can be found throughout the application as originally filed, and in the specification on page 8, lines 19-21.

Claims 16 and 17 have been amended to recite "at least one" pharmaceutically acceptable carrier, to avoid an unintended narrow reading of the claims. Support for this amendment can be found, among other places, in the specification on page 53, lines 4-8.

U.S. Patent Application No.: To be assigned
Attorney Docket No. 2481.1628-02

Please grant any extensions of time required to enter this Amendment and
charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 2, 2004

By: 

Jeremy M. Stipkala
Reg. No. 44,359

679306_1